ABTECT - Maintenance

Phase 3Active Not RecruitingNCT05535946

Abivax S.A.1,116 enrolled

Overview

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 study which consists of 2 treatment phases. This study consists of a 44-week maintenance treatment phase (Part 1 and Part 2), followed by a 4-year Long Term Extension (LTE) treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit. The maintenance phase is a 44-week double blind, placebo-controlled, phase. Subjects who are clinical responders after 8 weeks induction will be randomized to Part 1, and those who are non-clinical responders will be randomized to Part 2. At the end of the 44-week maintenance phase, subjects will continue their allocated treatment until the maintenance phase is unblinded. Once the study is unblinded, all subjects receiving obefazimod will continue their allocated treatment. Subjects receiving placebo will be allocated to obefazimod 25 mg or can terminate the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

1,116

Conditions

Ulcerative Colitis

Interventions

ABX464DRUG

Administered once daily, preferably in the morning, with food

PlaceboDRUG

Administered once daily, preferably in the morning, with food

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria in maintenance phase: * Subjects must have completed the induction treatment study (ABX464-105 or ABX464-106), and patients' clinical response status must be available. * Subjects with a valid endoscopy performed at the end of the induction study and results from central reader available at Day 1. * Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met. * Women of childbearing potential (WOCBP) subjects and male subjects with WOCBP partner must agree to comply with contraception requirements as described in Section 4.4. (Contraception) of the protocol. * Subjects must be able and willing to comply with study visits and procedures as per protocol. * Subjects should be affiliated to a health insurance policy whenever required by a participating country or state Inclusion criteria in LTE phase: * Subject must have completed the maintenance phase * Investigator and subject must assess and agree that the subject has received, and will continue to receive benefit from being in the study Exclusion Criteria in maintenance phase: * Subjects who permanently discontinued the study treatment during the induction study (either ABX464-105 or ABX464-106). * Subjects who have developed any major illness/condition (eg. primary sclerosis cholangitis, Crohn's disease, colectomy, diverting ileostomy, colon cancer or colonic adenomas \[low or high grade dysplasia\]). * Subjects with evidence of an unstable clinical condition (eg. toxic megacolon, fulminant colitis, bowel perforation, uncontrolled ischemic disease, congestive heart failure with NYHA class 3 or 4 symptoms) during the induction study that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study. * Subjects who plan to participate in other investigational studies during the maintenance study. * Male or female planning a pregnancy, or pregnant female subjects * Introduction during induction study of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea). * Any changes in the laboratory values during the induction period that could jeopardize subject's safety in the opinion of the investigator. If any doubts, the investigator should contact the sponsor study medical monitor. * Subject who is planning to receive live vaccine during the study. * Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities. Exclusion criteria for LTE phase: * Subject continues to satisfy exclusion criteria listed above for the maintenance phase * Introduction during maintenance phase of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea).

Locations (413)

Outcomes

Primary Outcomes

Rate of subjects in clinical remission at Week 44

The Part 1 primary objective is to compare the efficacy of ABX464 versus placebo on the proportion of subjects in clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Week 44.

Time frame: Week 44

Number and percentage of all treatment-emergent adverse events (TEAEs)

The Part 2 primary objective is safety

Time frame: Week 44

Number and percentage of all serious adverse events (SAEs)

The Part 2 primary objective is safety

Time frame: Week 44

Number and percentage of all causally related TEAEs/SAEs

The Part 2 primary objective is safety

Time frame: Week 44

Secondary Outcomes

Proportion of subjects with endoscopic improvement at Week 44

To compare the efficacy of ABX464 versus placebo on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1) at Week 44

Time frame: Week 44

Proportion of subjects with corticosteroid-free clinical remission

To compare the efficacy of ABX464 versus placebo on corticosteroid-free clinical remission (clinical remission at Week 44 and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry)

Time frame: Week 44

Proportion of subjects with sustained clinical remission at Week 44

To compare the efficacy of ABX464 versus placebo to sustain clinical remission at Week 44

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Digestive Health Specialists of the Southeast

Dothan, Alabama, United States

Research Solutions of Arizona, PC

Litchfield Park, Arizona, United States

GI Alliance

Sun City, Arizona, United States

University of Arizona

Tucson, Arizona, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Citrus Valley Gastroenterology

Covina, California, United States

University of California (San Diego)

La Jolla, California, United States

United Medical Doctors

Murrieta, California, United States

California Medical Research Associates Inc.

Northridge, California, United States

Clinnova Research Solutions

Orange, California, United States

...and 403 more locations

Proportion of subjects with HEMI per Geboes scoring at Week 44

To evaluate the efficacy of ABX464 on histologic-endoscopic mucosal improvement (HEMI) versus placebo at Week 44

Time frame: Week 44

Proportion of subjects with endoscopic remission at Week 44

To compare the efficacy of ABX464 versus placebo on endoscopic remission (MES = 0) at Week 44

Time frame: Week 44

LTE Phase - Proportion of subjects in clinical remission at Year 1

To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 1

Time frame: LTE Year 1

LTE Phase - Proportion of subjects in clinical remission at Year 4

To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 4

Time frame: LTE Year 4

LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry

To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and corticosteroid free for at least 12 weeks prior to Year 1 in the subpopulation with corticosteroids at maintenance study entry)

Time frame: LTE Year 1

LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry)

To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and corticosteroid free for at least 12 weeks prior to Year 4 in the subpopulation with corticosteroids at maintenance study entry)

Time frame: LTE Year 4

LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 1

To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)

Time frame: LTE Year 1

LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 4

To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)

Time frame: LTE Year 4

LTE Phase - Proportion of subjects with endoscopic remission at LTE year 1

To evaluate the efficacy of obefazimod on endoscopic remission ((Mayo Endoscopic Subscore (MES) = 0)

Time frame: LTE year 1

LTE Phase - Proportion of subjects with endoscopic remission at LTE year 4

To evaluate the efficacy of obefazimod on endoscopic remission (Mayo Endoscopic Subscore (MES) = 0)

Time frame: LTE year 4

LTE Phase - Proportion of subjects with CS-free symptomatic remission by visit

To evaluate the efficacy of obefazimod on CS-free symptomatic remission (symptomatic remission (SFS = 0 or 1 and RBS = 0) and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry) by visit (every 3-month)

Time frame: 4 years

LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 1

To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring

Time frame: LTE Year 1

LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 4

To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring

Time frame: LTE Year 4

LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 1

To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo

Time frame: LTE Year 1

LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 4

To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo

Time frame: LTE Year 4

LTE Phase - Proportion of subjects with sustained clinical remission at LTE Year 1, in the sub-population of subjects with clinical remission at Week 44

To evaluate the efficacy of obefazimod on sustained clinical remission Sustained clinical remission for the LTE is defined as clinical remission assessed at an endoscopy visit during the LTE in the sub-population of subjects in clinical remission at Week 44.

Time frame: LTE Year 1

LTE Phase - Proportion of subjects with sustained clinical remission at LTE year 4, in the sub-population of subjects with clinical remission at Week 44

Time frame: LTE year 4

LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 1, in the sub-population of subjects with endoscopic improvement at Week 44

To evaluate the efficacy of obefazimod on sustained endoscopic improvement

Time frame: LTE Year 1

LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 4, in the sub-population of subjects with endoscopic improvement at Week 44

To evaluate the efficacy of obefazimod on sustained endoscopic improvement

Time frame: LTE year 4

LTE Phase - Proportion of subjects with symptomatic remission by visit

To evaluate the efficacy of obefazimod on symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month)

Time frame: 4 years

LTE Phase - Proportion of subjects with sustained symptomatic remission by visit

To evaluate the efficacy of obefazimod on sustained symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month), in the sub-population of subjects with symptomatic remission at Week 44

Time frame: 4 years

LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 1

To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and CS-free for at least 12 weeks immediately prior to Year 1)

Time frame: LTE Year 1

LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 4

To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and CS-free for at least 12 weeks immediately prior to Year 4)

Time frame: LTE Year 4